prikaz prve stranice dokumenta Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
  Download
PDF 349.03 KB
Scientific paper - Case study
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
Journal of Neuroimmunology, 313 (2017); 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009
Rolla, Simona; De Mercanti, Stefania Federica; Bardina, Valentina; Horakova, Dana; Habek, Mario; Adamec, Ivan; Cocco, Eleonora; Annovazzi, Pietro; Vladić, Anton; Novelli, Francesco; Durelli, Luca; Clerico, Marinella

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Rolla, S., De Mercanti, S. F., Bardina, V., Horakova, D., Habek, M., Adamec, I. ... Clerico, M. (2017). Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology, 313., 89-91. doi: 10.1016/j.jneuroim.2017.10.009

Rolla, Simona, et al. "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses." Journal of Neuroimmunology, vol. 313, 2017, pp. 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009

Rolla, Simona, Stefania Federica De Mercanti, Valentina Bardina, Dana Horakova, Mario Habek, Ivan Adamec, Eleonora Cocco, et al. "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses." Journal of Neuroimmunology 313 (2017): 89-91. https://doi.org/10.1016/j.jneuroim.2017.10.009

Rolla, S., et al. (2017) 'Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses', Journal of Neuroimmunology, 313, pp. 89-91. doi: 10.1016/j.jneuroim.2017.10.009

Rolla S, De Mercanti SF, Bardina V, Horakova D, Habek M, Adamec I, and sur.. Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses. Journal of Neuroimmunology [Internet]. 2017 December 15 [cited 2024 April 29];313:89-91. doi: 10.1016/j.jneuroim.2017.10.009

S. Rolla, et al., "Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses", Journal of Neuroimmunology, vol. 313, pp. 89-91, December 2017. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:194192. [Accessed: 29 April 2024]

Metadata
Title (english)Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses
AuthorSimona Rolla
AuthorStefania Federica De Mercanti
AuthorValentina Bardina
AuthorDana Horakova
AuthorMario Habek
AuthorIvan Adamec
AuthorEleonora Cocco
AuthorPietro Annovazzi
AuthorAnton Vladić
AuthorFrancesco Novelli
AuthorLuca Durelli
AuthorMarinella Clerico
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Alemtuzumab, a highly effective treatment for relapsing remitting multiple sclerosis (RRMS), induces lymphopenia especially of CD4+ T cells. Here, we report the atypical CD4+ T population behaviour of two patients with persistent disease activity despite repeated alemtuzumab treatments. Whereas lymphocytes count decreased and fluctuated accordingly to alemtuzumab administration, their CD4+ cell percentage was not or just mildly affected and was slightly below the lowest normal limit already before alemtuzumab. These cases anticipate further studies aimed to investigate whether the evaluation of the CD4+ cell percentage could represent a helpful tool to address the individual clinical response to alemtuzumab.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Neuroimmunology
Numberingvol. 313, pp. 89-91
p-ISSN0165-5728
DOIhttps://doi.org/10.1016/j.jneuroim.2017.10.009
URN:NBNurn:nbn:hr:105:194192
Publication2017-12-15
Document URLhttps://doi.org/10.1016/j.jneuroim.2017.10.009
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 09:56:44